Table 1.
Baseline clinical and laboratory characteristics of sepsis patients.
Variables | Total (N = 176) | Survivors (N = 130) | Non-survivors (N = 46) | P value |
---|---|---|---|---|
Age (yr, IQR) | 80 (72, 88) | 78 (69, 87) | 83 (77.75, 90) | .004 |
Gender, n (%) | ||||
Male | 103 (58.52) | 82 (63.08) | 21 (45.65) | .039 |
Female | 73 (41.48) | 48 (36.92) | 25 (54.35) | |
Comorbidity, n (%) | ||||
Hypertension | 109 (61.93) | 78 (60.00) | 31 (67.39) | .375 |
Diabetes | 56 (31.82) | 40 (30.77) | 16 (34.78) | .615 |
Cardiovascular diseases | 45 (25.57) | 28 (21.54) | 17 (36.96) | .039 |
Cerebrovascular diseases | 54 (30.68) | 33 (25.38) | 21 (45.65) | .010 |
Chronic kidney diseases | 13 (7.39) | 8 (6.15) | 5 (10.87) | .293 |
Chronic liver diseases | 10 (5.68) | 8 (6.15) | 2 (4.35) | .933 |
Cancer | 10 (5.68) | 7 (5.38) | 3 (6.52) | 1.000 |
Primary site of infection, n (%) | ||||
Lung infections | 141 (80.11) | 100 (76.92) | 41 (89.13) | .075 |
Abdominal infections | 9 (5.11) | 8 (6.15) | 1 (2.17) | .507 |
Urinary tract infections | 3 (1.70) | 3 (2.31) | 0 (0.00) | .568 |
Other infections | 23 (13.07) | 19 (14.62) | 4 (8.70) | .442 |
APACHE II score, n (%) | ||||
0–10 | 57 (32.39) | 51 (39.23) | 6 (13.04) | .001 |
11–20 | 89 (50.57) | 62 (47.69) | 27 (58.70) | .200 |
21–30 | 25 (14.20) | 14 (10.77) | 11 (23.91) | .028 |
>30 | 5 (2.84) | 3 (2.31) | 2 (4.35) | .842 |
SOFA score, n (%) | ||||
0–5 | 101 (57.39) | 85 (65.38) | 16 (34.78) | <.001 |
6–10 | 64 (36.36) | 39 (30.00) | 25 (54.35) | .003 |
11–15 | 10 (5.68) | 6 (4.62) | 4 (8.70) | .511 |
>16 | 1 (0.57) | 0 (0.00) | 1 (2.17) | .586 |
Use of vasopressors, n (%) | 67 (38.07) | 28 (21.54) | 39 (84.78) | <.001 |
RBC (×1012/L, IQR) | 3.84 (3.18, 4.24) | 3.96 (3.19, 4.32) | 3.58 (3.06, 4.06) | .059 |
Hb (g/L, IQR) | 116.50 (96.25, 130.00) | 121.00 (96.00, 131.00) | 108.00 (96.75, 122.00) | .078 |
WBC (×109/L, IQR) | 11.26 (7.20, 15.94) | 10.93 (7.08, 15.25) | 12.83 (8.14, 18.17) | .099 |
NEUT (%, IQR) | 85.10 (76.43, 90.40) | 85.00 (73.40, 89.73) | 86.88 (81.60, 91.98) | .030 |
LY (%, IQR) | 7.45 (4.13, 13.08) | 7.85 (4.47, 14.00) | 6.10 (2.75, 10.83) | .046 |
PLT (×109/L, IQR) | 161.00 (100.00, 232.00) | 158.00 (95.00, 223.25) | 163.50 (114.00, 277.50) | .134 |
HCT (%, IQR) | 34.75 (28.30, 38.78) | 35.95 (28.30, 39.28) | 32.60 (28.93, 37.75) | .151 |
ALT (U/L, IQR) | 25.00 (14.25, 47.98) | 24.5 (14.00, 42.25) | 29.55 (14.75, 70.25) | .352 |
AST (U/L, IQR) | 32.00 (22.00, 60.00) | 31.00 (21.23, 45.43) | 37.25 (22.00, 103.48) | .098 |
STB (μmol/L, IQR) | 17.25 (10.83, 26.78) | 17.45 (10.78, 27.25) | 16.60 (10.75, 25.78) | .841 |
BUN (mmol/L, IQR) | 9.42 (5.87, 14.66) | 7.92 (5.39, 12.56) | 14.25 (8.99, 23.00) | <.001 |
Cr (μmol/L, IQR) | 83.40 (57.08, 127.35) | 79.25 (55.05, 124.68) | 99.05 (68.90, 169.75) | .020 |
K (mmol/L, IQR) | 3.70 (3.43, 4.30) | 3.65 (3.40, 4.12) | 4.10 (3.60, 4.50) | .003 |
Na (mmol/L, IQR) | 138.15 (134.00, 143.23) | 138.05 (134.00, 143.00) | 138.60 (132.78, 146.48) | .675 |
FIB (g/L, IQR) | 4.42 (3.45, 5.90) | 4.41 (3.54, 6.53) | 4.46 (3.25, 5.50) | .689 |
PT (S, IQR) | 13.50 (12.40, 15.60) | 13.50 (12.48, 15.10) | 14.45 (12.15, 16.93) | .251 |
APTT (S, IQR) | 30.50 (26.93, 36.88) | 30.05 (26.58, 37.80) | 32.30 (27.73, 36.55) | .273 |
D-D (mg/L, IQR) | 3.04 (1.67, 6.72) | 2.90 (1.57, 6.43) | 3.43 (2.12, 8.22) | .141 |
CRP (mg/L, IQR) | 65.22 (16.74, 121.19) | 65.78 (16.03, 136.82) | 58.11 (22.07, 105.76) | .976 |
PCT (ng/mL, IQR) | 0.87 (0.21, 4.96) | 0.78 (0.15, 5.59) | 1.14 (0.34, 3.19) | .304 |
ALT = alanine aminotransferase, APACHE II score = Acute Physiology and Chronic Health Evaluation II score, APTT = Activated Partial Thromboplastin Time, AST = aspartate aminotransferase, BUN = Blood Urea Nitrogen, Cr = Creatinine, CRP = C-reactive protein, D-D = D-dimer, FIB = fibrinogen, Hb = hemoglobin, HCT = hematocrit, K = Potassium, LY% = Lymphocyte, Na = Sodium, NEUT% = Neutrophil, PCT = Procalcitonin, PLT = platelet, PT = prothrombin time, RBC = Erythrocytes, SOFA score = Sequential Organ Failure Asses score, STB = Serum Total Bilirubin, WBC = leukocyte.